Ubiquitin-proteasome

Ubiquigent is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a (de)ubiquitylation (DUB) implicated in neurodegenerative, renal, and cardiovascular diseases.   Overseen by Professor Helen Walden, UoG, and Dr Mehmet Gundogdu, Principal Scientist at Ubiquigent, the project aims to combine biochemistry, in vitro complex protein assembly and […]

UK-based company Ubiquigent has signed an exclusive license with the University of Southern Denmark for its UbiSite technology. UbiSite will form a new component in Ubiquigent’s deubiquitylase (DUB) and ubiquitin-proteasome system (UPS) focused drug discovery platform. UbiSite technology uses an antibody specific to the C-terminal of ubiquitin for the capture and further identification of protein […]